Kairos Pharma, Ltd. (KAPA) is a publicly traded Healthcare sector company. As of July 15, 2026, KAPA trades at $0.33 with a market cap of $7.23M and a P/E ratio of -1.18. KAPA moved -4.82% today. Year to date, KAPA is -52.11%; over the trailing twelve months it is -50.37%. Its 52-week range spans $0.33 to $3.25. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces KAPA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for KAPA, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $0.33 |
| Market Cap | $7.23M |
| P/E Ratio | -1.18 |
| EPS | $-0.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.25 |
| 52-Week Low | $0.33 |
| Volume | 12.33M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-5.45M |
| Gross Margin | 0.00% |
1 analysts cover KAPA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.